CBC + Lipid Profile + Fasting Blood Sugar Test at Home

The CBC + Lipid Profile + Fasting Blood Sugar combination panel is one of the most clinically comprehensive single-draw screenings available for cardiometabolic risk. It brings together three investigative components: a Complete Blood Count, which evaluates the cellular composition of blood; a Lipid Profile, which quantifies the major cholesterol and triglyceride fractions that drive atherosclerosis; and a Fasting Blood Sugar, which screens for diabetes and impaired fasting glycaemia.

These three tests together address the four major independent cardiovascular risk factors that are modifiable: dyslipidemia, hyperglycemia, anemia (which increases cardiac workload), and the inflammatory profile hinted at by WBC and platelet patterns, in a single fasting blood draw. For adults with diabetes, hypertension, or a family history of early cardiovascular disease, this panel answers more clinical questions per blood draw than virtually any other equivalent-cost combination.

MAX@Home makes this panel available at home through a single morning fasting blood draw by a certified phlebotomist. Samples are processed at a partner NABL-accredited laboratory, and your digital authenticated report is delivered within 24 to 48 hours.

What the Complete Blood Count Measures in This Context

In the setting of a cardiometabolic screen, the CBC provides two specific and clinically relevant contributions beyond its routine diagnostic roles.

Anaemia and cardiovascular load

Anemia—hemoglobin below 13.5 g/dL in men and below 12.0 g/dL in women - forces the heart to pump a higher volume of blood to deliver adequate oxygen to tissues. This compensatory increase in cardiac output directly raises cardiovascular workload. In a patient already at elevated cardiovascular risk from dyslipidaemia and hyperglycaemia, coexisting anaemia is an additional independent burden on the heart. Iron deficiency anaemia, B12 deficiency anaemia, and anaemia of chronic disease are the three types most likely to be detected in an adult cardiometabolic screen, and the CBC's MCV and MCH indices point toward the most likely cause.

WBC and cardiovascular inflammation

Atherosclerosis is fundamentally an inflammatory disease, and chronic low-grade inflammation is a recognized cardiovascular risk amplifier. Elevated WBC within the normal-high range - particularly elevated monocytes, which migrate into arterial plaques and become foam cells - is associated with increased cardiovascular event risk in population studies. While the CBC is not a dedicated inflammatory marker (C-reactive protein and fibrinogen are more specific), a higher-than-usual WBC in the context of an elevated lipid panel alerts the clinician to consider a broader inflammatory workup.

Platelet count and thrombotic risk

Elevated platelet count (thrombocytosis) is associated with increased platelet aggregation and thrombotic tendency in some contexts - particularly in essential thrombocythaemia, a bone marrow disorder, and post-splenectomy states. For patients already at cardiovascular risk from dyslipidaemia, high platelets may add to thrombotic risk assessment. Low platelet count (thrombocytopaenia) in a patient on antiplatelet therapy for cardiovascular disease requires monitoring to prevent bleeding complications.

What the Lipid Profile Measures

The lipid profile quantifies the main circulating lipid fractions. Each fraction has a distinct relationship with cardiovascular risk, and reading them in combination is the standard of cardiovascular risk assessment in clinical practice.

Total cholesterol

Total cholesterol is the sum of all circulating cholesterol fractions: LDL-C, HDL-C, VLDL-C, and minor fractions. At the population level, total cholesterol above 200 mg/dL is associated with increasing cardiovascular risk. However, total cholesterol alone is a poor individual-level predictor because it includes both the harmful LDL fraction and the protective HDL fraction. A patient with total cholesterol of 210 mg/dL due to high HDL has a very different risk profile from one with the same total cholesterol driven by high LDL. Total cholesterol is most useful as a screening flag that prompts full lipid fraction analysis, which is exactly what the full lipid profile provides.

LDL cholesterol: the primary treatment target

LDL-C (low-density lipoprotein cholesterol) is the cholesterol fraction that penetrates arterial walls, becomes oxidised, and drives the atherosclerotic plaque formation underlying most heart attacks and strokes. LDL-C is the primary target of lipid-lowering therapy. Optimal LDL-C is below 100 mg/dL in the general population; below 70 mg/dL for patients with existing cardiovascular disease, diabetes, or CKD; and below 55 mg/dL for those with established atherosclerotic disease or very high risk. LDL-C is typically calculated using the Friedewald equation from total cholesterol, HDL-C, and triglycerides, though direct LDL assays are available for patients with very high triglycerides where the Friedewald estimate becomes unreliable.

HDL cholesterol: the protective fraction

HDL-C (high-density lipoprotein cholesterol) transports excess cholesterol from peripheral tissues back to the liver for excretion, a process called reverse cholesterol transport. High HDL-C is protective: HDL-C above 60 mg/dL is considered a negative cardiovascular risk factor. Low HDL-C (below 40 mg/dL in men, below 50 mg/dL in women) is an independent cardiovascular risk factor, particularly in the presence of elevated triglycerides, a pattern sometimes called the atherogenic dyslipidaemia triad, which is strongly associated with metabolic syndrome and type 2 diabetes.

Triglycerides: the metabolic signal

Triglycerides are the main storage form of dietary fat and are elevated after carbohydrate-rich or fat-rich meals, which is why the lipid profile must be collected fasting. Normal fasting triglycerides are below 150 mg/dL. Mild elevation (150 to 199 mg/dL) is borderline; moderate elevation (200 to 499 mg/dL) indicates hypertriglyceridaemia; severe elevation above 500 mg/dL carries a risk of acute pancreatitis. Elevated triglycerides accompany insulin resistance, type 2 diabetes, hypothyroidism, CKD, obesity, alcohol use, and certain medications including oral contraceptives, beta-blockers, and corticosteroids.

VLDL and non-HDL cholesterol

VLDL-C (very low density lipoprotein cholesterol) carries triglycerides in the bloodstream and is calculated as approximately one-fifth of the triglyceride value. Non-HDL cholesterol (calculated as total cholesterol minus HDL-C) includes LDL-C, VLDL-C, and other atherogenic particles. Non-HDL is increasingly used as a secondary treatment target because it captures a broader range of atherogenic lipoproteins than LDL-C alone. It is particularly useful when triglycerides are elevated and the Friedewald LDL-C estimate is unreliable.

The total cholesterol to HDL ratio

The TC:HDL ratio divides total cholesterol by HDL-C and provides a composite measure of atherogenic burden relative to the protective fraction. A ratio below 4 is generally considered acceptable; above 5 indicates elevated cardiovascular risk. This ratio is sometimes referred to as the atherogenic index and is used as a quick screening tool in risk communication.

What Fasting Blood Sugar Measures

Fasting blood sugar (FBS), also called fasting plasma glucose (FPG), measures the level of glucose in the blood after a minimum eight-hour fast. It is the most straightforward and widely used first-line test for detecting diabetes and impaired fasting glycaemia (IFG, sometimes called pre-diabetes).

Interpreting fasting glucose values

• Below 100 mg/dL: normal fasting glucose - no evidence of impaired glucose metabolism.
• 100 to 125 mg/dL: impaired fasting glycaemia (IFG) - commonly called pre-diabetes; risk of progression to type 2 diabetes is significant without lifestyle intervention.
• 126 mg/dL or above on two separate occasions: consistent with a diagnosis of type 2 diabetes. A single reading requires confirmation on a repeat fasting sample or an oral glucose tolerance test.

Why fasting matters so specifically for this test

Fasting glucose eliminates the post-prandial glucose rise that occurs after every meal, which can range from 30 to 80 mg/dL above baseline depending on the meal composition. Without fasting, glucose levels vary too widely to be clinically interpretable for diagnosis. The eight-hour minimum fast is also a prerequisite for an accurate lipid profile: non-fasting lipid values systematically underestimate LDL-C and overestimate triglycerides, making the lipid panel unreliable for treatment decisions.

The insulin resistance link connecting glucose, lipids, and CBC

Insulin resistance is the shared upstream driver of the combination of findings that this panel frequently uncovers: elevated fasting glucose (reflecting impaired glucose uptake), elevated triglycerides with low HDL (the atherogenic dyslipidaemia pattern of metabolic syndrome), and the mild normocytic anaemia commonly seen in inflammatory or metabolic states. When all three panels show their characteristic metabolic syndrome pattern simultaneously (marginally elevated glucose, high TG with low HDL, and subtle CBC changes), the clinical picture is stronger than any single abnormality alone, and the case for aggressive lifestyle intervention (and consideration of pharmacotherapy) is clearer.

Conditions This Panel Evaluates

Metabolic Syndrome

Metabolic syndrome is defined by three or more of the following features: central obesity, elevated fasting glucose, elevated triglycerides, low HDL-C, and elevated blood pressure. The CBC + Lipid Profile + Fasting Sugar panel directly addresses three of the five criteria (glucose, triglycerides, and HDL-C) while also screening for the haematological and inflammatory features that accompany the syndrome. Metabolic syndrome doubles the ten-year risk of cardiovascular events and increases the risk of type 2 diabetes fivefold.

Type 2 Diabetes — Screening and Monitoring

Type 2 diabetes is diagnosed from fasting glucose of 126 mg/dL or above on two occasions. Patients already known to have diabetes use the fasting sugar reading as one monitoring tool (though HbA1c reflects longer-term glycaemic control better). The lipid and CBC panels alongside fasting sugar give the treating clinician a complete picture of cardiovascular risk load in a diabetic patient, and diabetes is itself one of the strongest risk multipliers for adverse lipid effects on the coronary arteries.

Cardiovascular Disease Risk Assessment

The lipid profile, combined with fasting glucose, age, sex, blood pressure, and smoking status, forms the basis of formal cardiovascular risk calculators such as the Framingham risk score and the SCORE tool. For patients whose risk falls in the intermediate or high range, early initiation of statin therapy, antiplatelet therapy, and lifestyle modification significantly reduces ten-year event risk. The CBC adds anaemia and platelet data that are often missing from basic risk calculators but that carry independent prognostic significance.

Dyslipidaemia: Primary and Secondary

Primary dyslipidaemias (familial hypercholesterolaemia, familial combined hyperlipidaemia, and familial hypertriglyceridaemia) are genetic disorders identified by the pattern of lipid abnormalities in the profile. Secondary dyslipidaemias are caused by diabetes, hypothyroidism, CKD, obesity, and medications. The full lipid profile, read alongside fasting glucose and CBC, helps differentiate primary from secondary dyslipidaemia and identifies co-existing conditions that may need separate treatment.

Who Should Get This Test

• Adults above 30 for annual cardiovascular and metabolic risk screening.
• Patients with diabetes or pre-diabetes monitoring both glycaemic control and cardiovascular risk.
• Those with a family history of early heart disease (first-degree relative with heart attack or stroke before age 55 in men, 65 in women).
• Patients with obesity, particularly abdominal obesity, where metabolic syndrome risk is highest.
• Individuals on statin therapy needing periodic lipid response monitoring alongside CBC.
• Those prescribed oral contraceptives, corticosteroids, or beta-blockers, all of which adversely affect the lipid profile.
• Anyone with fatigue, unexplained weight gain, or risk factors for metabolic syndrome.

How to Prepare for the Test

The fasting requirement: strict and non-negotiable

A minimum eight-hour fast (and ideally ten to twelve hours) is required for this panel. Fasting is non-negotiable for both the lipid profile and fasting blood sugar; a non-fasting sample will make the lipid report unreliable and will produce a random glucose value that cannot be used for diabetes screening. Water may be consumed freely throughout the fast. Most patients find an overnight fast the most convenient approach, with the home visit scheduled for the following morning.

What to do the day before

• Eat a normal dinner the evening before the test; there is no need to eat differently the day before. The fast begins after dinner.
• Avoid alcohol the evening before. Alcohol temporarily raises triglycerides and can produce a falsely elevated reading the following morning.
• Avoid a particularly high-fat or high-carbohydrate dinner the night before if you want the most representative baseline lipid and glucose values.
• Continue all prescribed medications unless your doctor has specifically advised otherwise, including lipid-lowering and diabetes medications.

How to Book with MAX@Home

Booking this panel with MAX@Home requires no hospital visit.

1.  Visit the MAX@Home website or call the helpline and select the CBC + Lipid Profile + Fasting Blood Sugar panel.

2.  Schedule a morning appointment after an overnight fast, ideally between 7 and 10 a.m.

3.  A certified phlebotomist arrives at your home with all sterile collection equipment.

4.  A single blood draw provides all the material needed for CBC, lipid fractions, and fasting glucose.

5.  Samples are dispatched to a partner NABL-accredited laboratory under temperature-controlled conditions.

6.  Your digital authenticated report arrives within 24 to 48 hours to your registered contact.